in

IPO listing: immuno-oncology company Allogene Therapeutics (ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) was founded in 2017, headquartered in South San Francisco, California, USA, with 78 full-time employees (9/30/2018). It is a clinical stage immuno-oncology company focusing on genetic engineering and The development and commercialization of a kind of allogeneic T cell therapy for the treatment of cancer.

Allogene Therapeutics

Allogene Therapeutics (ALLO):

Allogene Therapeutics is a clinical stage biotechnology company that pioneered the development of allogeneic chimeric antigen receptor T cell (CAR T) therapy for cancer. Under the leadership of a world-class management team with rich experience in cell therapy, the company is developing an “off-the-shelf” CAR T cell therapy candidate drug, and its goal is to provide more patients with faster, more reliable and larger scale Cell therapy.

Allogene Therapeutics is developing a line of ready-made T cell candidates designed to target and kill cancer cells. The company’s engineered T cells are allogeneic, which means that they come from healthy donors and are used in any patient, rather than individual patients from the patient, as in the case of autologous T cells. Allogene Therapeutics believes that this key difference will enable us to provide ready-made treatment options to more patients faster, more reliably, and on a larger scale.

Allogene Therapeutics (ALLO) investment:

Allogene Therapeutics, Inc. (NASDAQ:ALLO) submitted its IPO prospectus on 9/14/2018, and landed on Nasdaq on 10/11/2018. The issue price was US$18.00, 16 million shares were issued, and US$288 million was raised. Underwriting by Goldman Sachs/ JP Morgan/ Cowen/ Jefferies.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Macau Casino Gaming and Entertainment Company: Studio City International Holdings (MSC)

Casino entertainment: Wynn Resorts (WYNN) (2002)